company background image
EDSA

Edesa Biotech NasdaqCM:EDSA Stock Report

Last Price

US$2.03

Market Cap

US$31.4m

7D

0%

1Y

-51.8%

Updated

18 Aug, 2022

Data

Company Financials +
EDSA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

EDSA Stock Overview

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs.

Edesa Biotech, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Edesa Biotech
Historical stock prices
Current Share PriceUS$2.03
52 Week HighUS$12.00
52 Week LowUS$1.30
Beta1.58
1 Month Change22.29%
3 Month Change11.54%
1 Year Change-51.78%
3 Year Change-49.75%
5 Year Changen/a
Change since IPO-60.96%

Recent News & Updates

Aug 12

Edesa Biotech GAAP EPS of -$0.37 beats by $0.06

Edesa Biotech press release (NASDAQ:EDSA): Q3 GAAP EPS of -$0.37 beats by $0.06. At June 30, 2022, Edesa had cash and cash equivalents of $12.81 million and working capital of $9.52 million.

May 16
Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

EDSAUS BiotechsUS Market
7D0%-2.0%1.4%
1Y-51.8%-22.2%-8.4%

Return vs Industry: EDSA underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: EDSA underperformed the US Market which returned -9% over the past year.

Price Volatility

Is EDSA's price volatile compared to industry and market?
EDSA volatility
EDSA Average Weekly Movement10.8%
Biotechs Industry Average Movement12.4%
Market Average Movement7.6%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.1%

Stable Share Price: EDSA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: EDSA's weekly volatility has decreased from 19% to 11% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201516Par Nijhawanhttps://www.edesabiotech.com

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10.

Edesa Biotech, Inc. Fundamentals Summary

How do Edesa Biotech's earnings and revenue compare to its market cap?
EDSA fundamental statistics
Market CapUS$31.39m
Earnings (TTM)-US$18.42m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EDSA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$18.42m
Earnings-US$18.42m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.19
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did EDSA perform over the long term?

See historical performance and comparison